CTMX CTMX
Company Profile ↓Company Overview
CTMX (CTMX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 27.5% per year over the last five years.
Revenue has grown at a 12.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $76.20M (-44.8% YoY); net profit $-17.37M.
- Trailing 12 Months Year-on-year growth — revenue -44.8%, earnings -154.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.8%, profit CAGR 27.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.75% |
| 1 Year: | -44.82% |
Compounded Profit Growth
| 5 Years: | 27.50% |
| 1 Year: | -154.50% |
Stock Price Performance
| 1 Year: | +40.17% |
| 6 Months: | -44.81% |
| 3 Months: | -17.89% |
| 1 Month: | -12.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.03 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.8% over 5 years.
- Profit CAGR of 27.5% over 5 years.
CONS
- Trading 50.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 11.65M | 8.75M | 24.14M | 27.07M | 14.18M | 21.34M | 12.51M | 11.47M | 29.48M | 9.01M | 10.71M | 8.28M | 49.59M | 16.61M | 17.79M | 15.97M | 16.29M | 17.59M | 9.04M | 12.85M | 11.15M | 23.50M | 24.72M | 26.38M | 41.46M | 25.11M | 33.43M | 50.92M | 18.66M | 5.96M | 10.26M |
| Operating Income | - | -4.87M | -5.54M | -11.27M | - | -16.18M | -14.26M | -14.92M | - | -8.61M | -25.37M | -11.03M | - | -15.63M | -13.26M | -23.18M | -25.81M | -16.57M | -31.23M | -25.72M | - | -2.79M | -16.14M | -14.89M | -15.63M | -19.20M | -22.64M | -32.06M | -30.05M | -29.71M | -5.65M | -3.35M | 3.12M | 11.66M | -8.45M | 4.11M | 22.62M | -1.29M | -15.77M | -19.67M |
| Net Income | -4.79M | -6.21M | -5.81M | -11.87M | -11.49M | -16.03M | -14.18M | -14.66M | -14.03M | -8.26M | -25.22M | -10.25M | 621.00K | -15.49M | -13.45M | -23.43M | -32.23M | -14.12M | -28.96M | -23.70M | -35.45M | 12.21M | -15.68M | -14.71M | -15.55M | -19.24M | -22.58M | -31.98M | -29.50M | -29.06M | -3.31M | -1.09M | 2.99M | 13.79M | -6.53M | 5.74M | 23.52M | -154.00K | -14.23M | -18.25M |
| R&D Expense | - | 4.66M | 5.03M | 9.16M | - | 13.37M | 12.71M | 13.34M | - | 14.58M | 28.08M | 28.92M | - | 22.46M | 25.55M | 27.55M | - | 36.38M | 30.84M | 27.97M | - | 42.81M | 24.07M | 24.05M | 22.37M | 26.10M | 29.14M | 30.56M | 31.16M | 30.37M | 21.18M | 20.67M | 16.45M | 22.05M | 25.17M | 21.37M | 18.87M | 13.32M | 15.30M | 19.24M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 888.00K | 5.08M | 7.71M | 12.85M | 71.62M | 59.50M | 57.49M | 100.36M | 37.31M | 53.16M | 101.21M | 138.10M | 76.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 154.50M | 107.70M | 113.11M | 98.56M |
| Operating Income | -14.96M | -29.77M | -33.20M | -59.59M | -46.26M | -77.87M | -110.89M | -48.60M | -116.04M | -101.33M | -6.48M | 25.00M | -22.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | -98.89M | -4.31M | 26.76M | -20.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -99.32M | 3.32M | 32.09M | -17.13M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 3.89M | 224.00K | 238.00K |
| Net Income | -15.14M | -30.31M | -35.37M | -58.90M | -43.10M | -84.60M | -102.24M | -32.88M | -115.87M | -99.32M | -569.00K | 31.87M | -17.37M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -1.51 | -0.01 | 0.38 | -0.15 |
| R&D Expense | 10.89M | 28.30M | 28.36M | 54.76M | 92.28M | 103.87M | 131.62M | 112.94M | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 73.06M | 197.22M | 199.13M | 397.64M | 457.11M | 341.28M | 358.66M | 339.41M | - | - | - | 260.89M | 201.79M | 120.53M | 151.57M |
| Total Equity | -26.05M | -44.28M | -78.54M | 126.07M | 78.48M | 69.90M | 130.88M | 51.11M | -7.77M | -459.00K | -29.74M | -54.54M | -80.54M | -85.75M | -47.45M | -456.00K | 99.01M |
| Cash & Equivalents | 14.75M | 8.70M | 64.40M | 59.82M | 104.64M | 177.55M | 247.58M | 188.43M | 191.86M | 205.53M | - | - | - | 193.65M | 17.17M | 38.05M | 12.67M |
| Long Term Debt | - | - | 1.57M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 74.89M | 71.15M | 120.65M | 327.75M | 326.23M | 290.17M | 308.86M | 339.87M | 326.56M | 314.62M | 307.03M | 346.64M | 249.24M | 120.99M | 52.56M |
| Current Liabilities | - | - | 11.16M | 15.74M | 35.77M | 61.15M | 97.91M | 85.59M | 100.92M | 77.87M | 87.40M | 94.64M | 123.64M | 152.61M | 155.91M | 85.77M | 46.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -2.03M | 170.37M | -75.52M | -140.48M | 5.26M | -119.03M | -110.79M | -56.03M | -86.23M | -75.59M |
| Investing Cash Flow | - | - | - | 45.86M | -121.27M | 5.93M | 79.70M | -18.72M | 22.49M | 98.26M | -150.67M | 99.70M | -59.74M |
| Financing Cash Flow | - | - | - | 996.00K | 23.80M | 139.62M | 1.63M | 16.89M | 110.21M | 648.00K | 30.23M | 7.52M | 110.45M |
| Capital Expenditure | -732.00K | -1.66M | -1.59M | -2.18M | -1.56M | -3.79M | -3.50M | -2.31M | -1.61M | -1.74M | -840.00K | -310.00K | -220.00K |
| Free Cash Flow | - | - | - | -4.21M | 168.81M | -79.31M | -143.98M | 2.95M | -120.64M | -112.53M | -56.88M | -86.54M | -75.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,684.2% | -586.3% | -430.5% | -463.9% | -64.6% | -130.9% | -192.9% | -48.4% | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Net Margin % | -1,705.3% | -597.0% | -458.7% | -458.5% | -60.2% | -142.2% | -177.8% | -32.8% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| ROE % | 34.2% | 38.6% | -28.1% | -75.1% | -61.7% | -64.6% | -200.0% | 423.0% | 25,244.0% | 115.8% | 1.2% | -6,988.8% | -17.5% |
| ROCE % | - | -48.1% | -18.3% | -36.5% | -13.7% | -21.7% | -43.4% | -18.9% | -44.4% | -93.6% | -14.1% | 71.9% | -21.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTMX
Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQNnpjTHVVdS1uNElZZmNwQWUybFRhX19QZ1FOQmN0YnNOQWFWWWd4NHVjRXYwMXF0aktaTG1ON3hmMEpObjRWM3dwbzhzZ1YyMlJzMFNGWE42Mjl3dDR4dERITE14QVJiZG9WdnB2TGVaa09hT24tdkxRX29MaVNDcVhFLUpkV01HMHhBMH…
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNN3FDUGt3azNGNGtWbl8xYXN0cU5Gczl0SUJPT3F2Zk5pWHc3WXRhand0REVLMlpHVnZzcTZYUzRmT3R5RTRKUWhBdWt0UFN3ZFRIN25EeF9RcFFubDdaV0lud3BYUGNPcVJFX3ZWX0JnYU9HRUlDRDdYNndQYjRLZG1PU3V6RjZxcldyRD…
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNQWFidHN1eks4SUxKeU1QXzlQaGRpR29nOFZua2puaVFRRl9PUElCWFA4Q0VnOFltWlgtTDBPV09LUWUzUnBCRlNyX1luV21QeS1ZVlN5UGFEelN4cklHekVrTVg4MV9ER09ETWl1cUxCYUJOX2dnNFJnMkFCMndnM0d4bw?oc=5" targe…
CytomX Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNd1JaZ0RQam8xeHpoejRzaE85WEt5bUMwd1FVQ1ZQOHBaZ2hSdnJvYUNjcDUwb0tDWGVpMlJsVDVjLUVZaV9qTWI0V2I3Zlo0NjRaZnl0dmx1b2JKaE9oY3dSczFHUXVmWVNGXy14VUp4NXYzc1ItTER5ZjUtc19OU0t0d1IzTFZCTnZzbj…
CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOTE1PcFcwX2lVb0NLLV8xa1BubTFmdUtfMDg5ZkoxVWdJckc3ZnRUR1p0VnlFazNuTl9YX3I5TUZDNlg1U3FrY0oyd0JzVHo2R1RraG1vQkVoeUZXc3lEa29LcDFVQlRJUy1vcXlDZ0xtWXZXV0ktVHJYOUduLUdsSTNwNUxhdnVPZjF4S2…
Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNTHVuOEg1ZlQyeXJXRGpCWWQzQ0ZEZ2VMS3ZkTEQ5TlpvS05HbWExdXlZaV9sN0dGcVYxbFQ0Q3JyZUdYcFF1d1JMd2szRVlSZG9CZHJHckYzOHpvbkU1NTBkdEJLZnQ3a0dkb01BRG81VzVrLVl1RkllYTZGSkZpWFFISkYzY3ZWM01XSX…
CTMX — Frequently Asked Questions
What is the current share price of CTMX?
As of 2026-08-05 17:25 PDT, CTMX trades at $3.35 on NASDAQ/NYSE. Its 52-week range is $1.76 to $6.75.
What is the P/E ratio of CTMX?
CTMX trades at a trailing price-to-earnings (P/E) ratio of -22.33.
What is the return on equity (ROE) of CTMX?
CTMX has a return on equity (ROE) of -17.54%. Its return on capital employed (ROCE) is -21.31%.
Is CTMX a good stock to buy?
This page provides a data-driven analysis of CTMX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.